Vice President of R&D and Quality Management

Dr. Xiangping Zhu is responsible for the development and quality management of Rongxie. Dr. Zhu graduated from Rutgers University in the United States with a PhD in chemistry and has more than two decades of experience in biopharmaceutical CMC development and quality management.

Dr. Zhu has worked for companies such as Applied Biosystems, Johnson & Johnson Momenta, Pharmatobiology, Jeko Biologics, and Tianjing Biologics, including senior scientist and senior executive positions. During this period, he led and participated in the development of complex molecular drugs, including the polysaccharide drug Lovenox generic, the peptide drug Copaxone generic, and the development of multiple monoclonal, double-clonal and fusion proteins, of which the generic Lovenox and the generic Copaxone generic have entered commercial production. A number of monoclonal antibodies, double antibodies and fusion protein drugs entered phase 1-3 clinical trials.

Dr. Zhu holds more than ten European and American patents.

Production vice manager

He has worked in the production, technology and management positions of domestic and foreign pharmaceutical enterprises for nearly 30 years, and has experience in the research and production of antibiotics, genetically engineered drugs and heparin drugs, and is good at the development and production of solid preparations and freeze-dried preparations.

Familiar with CFDA /FDA regulations, experienced many GMP certification activities in China, the United States, Europe and Japan. With pharmaceutical plant preparation, planning and design and operation management ability.

He worked for SPL China.

Responsible for the financial work of the company.

I graduated from Jiangxi University of Finance and Economics, majoring in Auditing (full-time undergraduate), and from the Chinese University of Hong Kong, majoring in Accounting (part-time master). I have rich experience in the fields of capital operation, financial management and tax planning. As a certified public accountant, I used to work as the department head of Tianjian Accounting Firm and the financial director of several prospective listed companies. He has rich experience in listing regulations, domestic capital market financing process and other aspects, and has led and participated in the IPO work of a number of companies to be listed.

Graduated from Fudan University .

She has served as general manager of Human Resources, CEO of travel guide & information Division, vice president and honorary partner in Ctrip .

She has rich experience in combining company strategy analysis, business logic and team building strategies ， which could encourage growth of employees and build high-performance teams.

Responsible for R&D of pipeline technology and project management

Jiangnan University, Master of Biochemistry and Molecular Biology, founding member of Rongyu, with more than 10 years of drug research and development experience, focusing on the development of complex molecular drugs such as polysaccharides, peptides and nucleic acids, and rich experience in the fields of asymmetric synthesis of chiral drugs, enzyme fermentation, enzyme and biocatalysis and transformation, and pharmaceutical preparations CMC. Scientific research results involved non-porcine (sheep, cattle) heparin and low molecular weight heparin derivatives (sheep enoxaparin sodium, sheep low molecular weight heparin, etc.), depolymerized sea cucumber glycosaminoglycan, glatil and enzyme catalyzed chiral drugs, and so on, the first inventor of more than ten patents.

Suzhou Ronnsi Biotechnology Co., Ltd. was established in November 2012,It is a high-tech enterprise dedicated to the research of cutting-edge complex molecular drug analysis and characterization technology.Fusion biology integrates biological information, enzyme technology and analysis technology to build a complex molecular drug platform to complete the composition and structure analysis of complex molecular drugs...